Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
出版年份 2021 全文链接
标题
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 126, Issue 1, Pages 120-128
出版商
Springer Science and Business Media LLC
发表日期
2021-11-04
DOI
10.1038/s41416-021-01609-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
- (2021) Michal M Hoppe et al. EMBO Molecular Medicine
- PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
- (2021) Hélène Vanacker et al. CANCER TREATMENT REVIEWS
- The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
- (2021) Margherita Turinetto et al. Frontiers in Oncology
- VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
- (2021) Francesca Bizzaro et al. Journal of Hematology & Oncology
- Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
- (2020) Neha Chopra et al. Nature Communications
- Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
- (2020) Paul DiSilvestro et al. JOURNAL OF CLINICAL ONCOLOGY
- ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
- (2020) R.E. Miller et al. ANNALS OF ONCOLOGY
- Homologous recombination deficiency real-time clinical assays, ready or not?
- (2020) Katherine Fuh et al. GYNECOLOGIC ONCOLOGY
- Clinical assays for assessment of homologous recombination DNA repair deficiency
- (2020) Elizabeth H. Stover et al. GYNECOLOGIC ONCOLOGY
- Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
- (2020) Federica Guffanti et al. Cancers
- PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
- (2020) William P. Tew et al. OBSTETRICAL & GYNECOLOGICAL SURVEY
- Platinum Resistance in Ovarian Cancer: Role of DNA Repair
- (2019) Giovanna Damia et al. Cancers
- Epithelial ovarian cancer
- (2019) Stephanie Lheureux et al. LANCET
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting deubiquitinase USP28 for cancer therapy
- (2018) Xiaofang Wang et al. Cell Death & Disease
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
- (2018) Federica Guffanti et al. Oncotarget
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage
- (2018) Jana Slyskova et al. NUCLEIC ACIDS RESEARCH
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
- (2018) Marta Castroviejo‐Bermejo et al. EMBO Molecular Medicine
- PARP inhibitors in ovarian cancer
- (2018) Elisena Franzese et al. CANCER TREATMENT REVIEWS
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Repair Pathway Choices and Consequences at the Double-Strand Break
- (2016) Raphael Ceccaldi et al. TRENDS IN CELL BIOLOGY
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study
- (2015) L. Beltrame et al. ANNALS OF ONCOLOGY
- A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
- (2015) R. Ceccaldi et al. CANCER RESEARCH
- Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance
- (2015) Peter Bai MOLECULAR CELL
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
- (2014) F. Ricci et al. CANCER RESEARCH
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Verification of complete bisulfite modification using Calponin-specific primer sets
- (2009) Ruethairat Sriraksa et al. CLINICAL BIOCHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search